MEENAKSHI HEGDE to Immunotherapy, Adoptive
This is a "connection" page, showing publications MEENAKSHI HEGDE has written about Immunotherapy, Adoptive.
Connection Strength
2.418
-
A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. Cancer Res Commun. 2025 Mar 01; 5(3):527-548.
Score: 0.605
-
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024 06; 5(6):880-894.
Score: 0.570
-
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020 07 15; 11(1):3549.
Score: 0.439
-
Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors. Pediatr Blood Cancer. 2025 Apr; 72(4):e31557.
Score: 0.150
-
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
Score: 0.143
-
Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021 06; 18(6):379-393.
Score: 0.114
-
Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020 05; 26(5):720-731.
Score: 0.108
-
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia. 2021 01; 35(1):75-89.
Score: 0.107
-
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
Score: 0.083
-
Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68.
Score: 0.061
-
Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells. Sci Adv. 2025 Jan 10; 11(2):eadq8114.
Score: 0.037